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Abstract 
Polypharmacy among older adults in long-term care facilities is a relevant issue, which leads to 
an increase in health care costs and adverse drug reactions.  The implementation of 
comprehension medication reviews or medication reconciliation identifies and helps reduce 
polypharmacy.  Evidence shows that nurses help to alleviate polypharmacy through 
comprehensive medication reviews.  The purpose of this DNP project was to reduce 
polypharmacy among adults 65 years and older through the implementation of the Screening 
Tool to Older Person’s Prescriptions (STOPP) and Screening Tool to Alert Doctors to the Right 
Treatment (START) while conducting medication reconciliation.  This quality improvement 
project occurred at two sites of a long-term care facility in eastern North Carolina for 
developmentally disabled adults.  The licensed practical nurse (LPN) and registered nurse (RN) 
team leader were educated on medication reconciliation and trained to use the STOPP/START 
tool.  The results revealed that 100% of older adults (N = 11) pre-implementation and post-
implementation had polypharmacy.  There was one patient by the end of the project that had a 
reduction in medication orders and potentially inappropriate medications.  Future projects should 
focus on implementing medication reconciliation with every medication change and transitions 
of care, including provider education and participation, to have an increasing impact on the 
reduction of polypharmacy. 
Key words:  polypharmacy; polypharmacy in older adults; potentially inappropriate 
medication; potentially inappropriate prescribing; adverse drug reaction 
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Chapter One:  Overview of the Problem of Interest   
Polypharmacy occurs more often among older adult patients than younger patients due to 
chronic health condition sequelae (Morin et al., 2018).  Healthcare professional assessment tools 
can prevent polypharmacy among older adults (Alpert & Gatlin, 2015).  According to Alpert & 
Gatlin (2015), using validated assessment tools in older adults' medications commonly 
prescribed can decrease polypharmacy.  Validated medicine assessment tools help prevent 
adverse drug events among older adults (Alpert & Gatlin, 2015).  The purpose of this chapter is 
to present information on this Doctor of Nursing Practice (DNP) quality improvement (QI) 
project about increasing polypharmacy assessment among older adults in long term care.  
Background Information  
  As patients age, health problems increase, resulting in multiple medications to treat 
comorbidities.  According to Maher, Hanlon, & Hajjar (2017); Morin et al. (2018), 
polypharmacy is the use of five or more drugs taken by an individual.  Jokanovic, Tan, Dooley, 
Kirkpatrick, & Bell (2015), observed that an elaborate medication plan is a result of several 
comorbidities among older adults.  More than 40% of older adults are affected by polypharmacy 
(Maher, Hanlon, & Hajjar, 2014; Morin et al., 2018).  Polypharmacy correlates with a heightened 
risk of adverse drug events (Brown, 2016).  Polypharmacy is linked to many undesirable 
outcomes such as the risk for falls, adverse drug reactions (ADR), and hospital readmissions 
(Maher, Hanlon, & Hajjar, 2014; Masnoon, Shakib, Kalisch-Ellett, & Caughey, 2017).  Adverse 
drug reactions account for almost 10% of hospitalizations among older adults (Jokanovic et al., 
2015).   Medication elimination is slower, which alters pharmacokinetics and pharmacodynamics 
to a degree of potential harm (Morin et al., 2018). 
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According to Masnoon et al. (2017), a potentially inappropriate medication occurs when 
a risk of adverse drug events exceeds a medication 's beneficial use.  Potentially inappropriate 
medications are common among older adults with many chronic diseases.  Polypharmacy may be 
clinically relevant for some older adults.  Still, as health care providers, it is necessary to identify 
older adults that may be at an increased risk of adverse drug events related to inappropriate 
medications (Masnoon et al., 2017).  
Many evidence-based tools can determine inappropriate medicines in older adults (Alpert 
& Gatlin, 2015; Dagli & Sharma, 2014; Masnoon et al., 2017).  It is essential to evaluate 
polypharmacy to reduce adverse events among older adults (Dagli & Sharma, 2014).  Assessing 
polypharmacy is done through medication review or reconciliation by the healthcare team (Dagli 
& Sharma, 2014; Gooen, 2017; IHI, 2019a).  According to Masnoon et al. (2017), the Beers 
Criteria is a validated tool used to identify potentially inappropriate medications, reducing 
polypharmacy.  Other validated tools include (1) Screening Tool to Older Person’s Prescriptions 
(STOPP) (2) Screening Tool to Alert Doctors to the Right Treatment (START) and (3) Assess 
Review Minimize Optimize Reassess (ARMOR) (Dagli & Sharma, 2014). 
Validated tools.  Many validated tools have evidence that has shown to be appropriate in 
identifying potentially inappropriate medications.   
Beers Criteria.  The American Geriatrics Society developed the Beers Criteria.  The 
Beers Criteria constructed a list of potentially inappropriate drugs that older adults should avoid 
when diagnosed with certain conditions (AGS, 2019; Masnoon et al., 2017). 
STOPP/START.  The STOPP/START tool identifies potentially inappropriate 
medications that are prescribed to older adults by conditions.  A section of the STOPP/START 
emphasizes medicines that are not commonly ordered for older adults when they show benefit in 
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certain situations (Alpert & Gatlin, 2015; Dagli & Sharma; Hernandez, 2017; O’Mahony et al., 
2015). 
ARMOR.  The ARMOR is a tool designed to be used by the interdisciplinary healthcare 
team.  The process of the ARMOR tool is to assess, review, minimize, optimize, and reassess to 
evaluate polypharmacy in older adults (Dagli & Sharma, 2014; Hernandez, 2017).  This tool 
reduces polypharmacy with the goal of quality of life (Hernandez, 2017). 
Significance of Clinical Problem  
 Polypharmacy contributes to patient hazards in long term care facilities (Arnoldo, 
Cattani, Cojutti, Pea, & Brusaferro, 2016).  According to Charlesworth, Smit, Lee, Alramadhan, 
& Odden (2015), from 1988 to 2010, prescriptions of five or more medications for older adults 
tripled to almost 40%.   All prescription medications pose risks (Charlesworth et al., 2015).  The 
more medications an older adult consumes, the higher the chance is for adverse drug-related 
events (Guharoy, 2017; Morin et al., 2018).  Adverse drug events increase the probability of 
mortality in older adults. 
Polypharmacy contributes to increased health care costs for the patient and healthcare 
organizations.  Older adults that consume many medications are prone to many healthcare visits 
(Charlesworth et al., 2015).  Polypharmacy increases the number of outpatient visits and 
hospitalizations, which increases health care costs for patients and healthcare systems (Guharoy, 
2017; Jokanovic et al., 2015; Maher, Hanlon, & Hajjar, 2014).  The Centers for Disease Control 
and Prevention (2018) stated that there are about 1.3 million patient visits to the emergency 
department, resulting in approximately 350,000 hospitalizations annually related to adverse drug 
events.  Polypharmacy induced adverse drug events drive medical costs beyond $3.5 billion 
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(CDC, 2018).  According to Jokanovic et al. (2015), being knowledgeable about polypharmacy, 
and developing a plan to reduce it can decrease patient health care costs and mortality. 
 An interview completed with the Chief Nursing Officer (CNO) of a long-term care 
facility in eastern North Carolina.  The CNO stated that there were several residents in multiple 
sites that received excessive medication; almost 95% of the residents within two facilities 
considered to have polypharmacy (CNO, personal communication, February 2019).  According 
to the CNO, many residents were taking a duplicate class of medications, which contributed to 
excessive drugs at two facilities (CNO, personal communication, February 2019).  The CNO 
stated that an LPN conducts monthly medication reviews when the batch medications are 
checked into the facility.  The batch medications are medications that are automatically filled 
monthly in a cycle.  The batch medications include all medications except liquids, eye drops, 
nasal sprays, and topicals; these items require individual refill request every 30 days.  The 
monthly medication reviews conducted by the LPN include comparing medications to the 
updated and most accurate provider orders.  These medication reviews do not identify duplicate 
classes of medicines that may cause adverse events (CNO, personal communication, February 
2019).  The CNO stated that state regulations require a pharmacist to review drug utilization 
every three months at each facility (CNO, personal communication, February 2019).  The 
pharmacist drug utilization review gives recommendations to nurses and physicians about 
changes that can be made to a resident’s medication regimen (CNO, personal communication, 
February 2019).   
While working with this long-term care facility, it was evident that the facilities needed 
to develop strategies in reducing polypharmacy.  The facilities need to intervene to prevent 
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adverse reactions and events among the residents resulting in more emergency room visits or 
stays at the hospital. 
Question Guiding Inquiry (PICO)  
In older adults residing in a long-term care facility, how does training, and using the 
STOPP/START criteria compare to once monthly medication review affect the reduction of 
polypharmacy and potentially inappropriate medications? 
 Population.  The population of this project was the Licensed Practical Nurses working 
within the facility daily and the Registered Nurse that supervises the facility. 
Intervention.  The intervention was to train the Licensed Practical Nurses and Registered 
Nurses on a validated tool.  The validated tool included the STOPP/START criteria to identify 
potentially inappropriate medications, with provider alerts to discontinue medication, if needed. 
Comparison.  The occurrence of polypharmacy and potentially inappropriate 
medications in older adults before and after nurses received education about the STOPP/START 
criteria. 
Outcome(s).  The intended outcome was to reduce polypharmacy and potentially 
inappropriate medication occurrences among older adults.  New policy development requires 
nurses to complete comprehensive medication reviews to increase safety among older adults. 
Summary  
 Polypharmacy is associated with safety among older adults.  Polypharmacy has a high 
prevalence among older adults residing in long term care facilities.  Multiple comorbidities 
increase an older adult's chance of taking more medications.  Older adults are at an intensified 
risk of undesirable drug events (falls, geriatric syndromes, and drug-drug interactions), which 
increases the need to reduce polypharmacy.  Evidence indicates that evidence-based tools can 
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reduce polypharmacy or potentially inappropriate medication.  At times, multiple medications 
may be appropriate for older adults.  However, it is relevant to assess to reduce potentially 
inappropriate medications.   Combating polypharmacy and potentially inappropriate medications 
can reduce (1) adverse drug events, (2) office visits and hospitalizations, and (3) healthcare costs.  
Polypharmacy is a problem; evaluation of evidence to establish a solution that is beneficial 
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Chapter Two:  Review of the Literature  
The purpose of this literature review was to understand polypharmacy and its effects.  
This literature review describes evidence-based practice interventions that reduce polypharmacy.  
Reviewing the related topics allows one to understand the importance of reducing polypharmacy. 
Literature Appraisal Methodology  
Sampling strategies.  The literature review was completed using the databases PubMed, 
Medline via Ovid, Google Scholar, and Cumulative Index of Nursing and Allied Health 
(CINAHL).  The search terms used were polypharmacy, polypharmacy in older adults, 
polypharmacy in older adults in long term care facilities, polypharmacy in elderly people, 
polypharmacy in the aged, inappropriate prescribing, potentially inappropriate medication, and 
potentially inappropriate prescribing.  The MeSH (Medical Subject Headings) terms used were 
humans, long-term care, polypharmacy, prevalence, adult, aged, aged 80 and over, education, 
nursing, medication therapy management, and education, nurse's role, nursing staff, and 
education, and patient education topics.   The searches were limited to adults only.  The articles 
were limited to the English language and published from February 2014 to the present date. 
Evaluation criteria.  The literature review articles had several inclusion and exclusion 
criteria.  The initial search on PubMed returned over two-thousand articles using the search term 
polypharmacy; however, the studies did not address older adults.  The inclusion criteria were 
polypharmacy in male or female, older adult (65 years or older) population, and residing in long-
term care facilities.  The inclusion criteria also included interventions for polypharmacy and 
potentially inappropriate medications.  Included were studies published within the last five years.  
After the search was concluded, seven articles were kept and reviewed.  The flow diagram 
presented additional detail about study selection (see Appendix A). 
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The level of evidence was assessed with the Melnyk & Fineout-Overholt's (2011) model 
because it describes hierarchy evidence.  There were seven levels of evidence with level one 
displaying the most rigorous data.  Most of the evidence were systematic reviews with 
randomized control trial (RCTs).  
 This search focused on interventions to reduce polypharmacy.  The literature review 
included multiple levels of evidence (see Appendix B).   
Literature Review Findings  
After completing the literature review, level one evidence was the typical findings.  Level 
one evidence comprises randomized controlled trials, systematic reviews, and meta-analyses.  
Some studies reported clinical guidelines based on systematic reviews.  One study was a cohort 
and a case-control study. 
Polypharmacy.  Polypharmacy is a rising concern for older adults in the United States.  
Morin et al. (2018) found that polypharmacy had several definitions, all inconsistent.  A 
systematic review of RCTs completed on the precise meaning of polypharmacy (Masnoon et al., 
2017).  According to Masson et al. (2017), results of a systematic review indicated more than 
130 definitions for polypharmacy.  The study reported that about 80% of the definitions were 
numerical instead of descriptive (Masson et al., 2017).  As an example, polypharmacy was 
described as several medications, inappropriate medications use, or what most prescribers 
considered unnecessary (Jokanovic et al., 2015).  The most appropriate definition, used among 
half the studies, was the consumption of five or more medications per day (Masnoon et al., 
2017).  Another term used was appropriate prescribing (Masnoon et al., 2017).   Older adults 
consuming multiple prescribed or over-the-counter medications are at a higher risk of needing to 
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be seen by the provider more often.  The more visits with the provider, the more healthcare cost 
increased related to polypharmacy.  
Safety.   Polypharmacy is considered a patient safety concern (Arnoldo et al., 2016).  
Polypharmacy was often related to older adults with comorbidities (Jokanovic et al., 2015).  
Jokanovic et al. (2015) wrote that the complexity of the medication regimen was secondary to 
comorbidities in older adults.  In long-term care facilities, there was an increase in polypharmacy 
among its older residents (Arnoldo et al., 2016).  Polypharmacy increases the risk of adverse 
events in older adults (Alpert & Gatlin, 2015).   Adverse events in older adults included falls, 
severe drug reactions, and decreased medication compliance (Alpert & Gatlin, 2015).  The 
literature states that at least 40% of all older adults have reduced renal function (Alpert & Gatlin, 
2015).   The decreased renal function increases older adults’ risk for adverse drug events 
(Masnoon et al., 2017).  Older adults have reduced drug elimination, which results in an 
abnormal level of drugs (Wooten, 2015).  Thus, it is essential to reduce the number of 
medications among older adults, to optimize renal function.   
Medication review.  The literature states that nurses help eliminate polypharmacy 
(Brown, 2016).  A systematic review of RCTs conducted to reduce polypharmacy and 
inappropriate medications through comprehensive medication reviews (Brown, 2016).  A nurse 
should complete routine medication reviews on older adults living in long-term care facilities 
(Alpert & Gatlin, 2015).  In the project site, medication reviews were infrequently completed.  
Specifically, they are completed monthly at the project site.  The project site does not have a 
policy of medication reconciliation utilizing validated instruments to help nurses determine if an 
older adult is consuming inappropriate medications.  Nurses were using clinical judgment to alert 
prescribers about adverse medication-related events.   
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Interventions.  The literature states that frequently used is the BEERs Criteria tool to 
assess older adults are on safe medications (Alpert & Gatlin, 2015).  There was one literature 
review on interventions to polypharmacy and potentially inappropriate medications.   When 
using a validated tool, such as BEERs Criteria, healthcare staff can identify drugs that may be 
inappropriate (Alpert & Gatlin, 2015).  There are several other tools:(1) Screening Tool to Older 
Person’s Potentially Inappropriate Prescriptions; (2) Screening Tool to Alert Doctors to the Right 
Treatment (STOPP/START); and (3) Assess Review Minimize Optimize Reassess (ARMOR) to 
address polypharmacy or prescribing errors (Alpert & Gatlin, 2015).  The STOPP/START tool is 
a shorter version of the BEERs Criteria.  The STOPP/START tool developed to identify further 
common prescribing patterns that may result in an error.  For example, (1) if older adults were 
receiving the same class of medication (2) Lasix usage in an older adult with edematous 
extremities, without HF diagnosis (3) prescribing tricyclic antidepressants in older adults with 
glaucoma (Alpert & Gatlin, 2015).  The ARMOR can be used by anyone on the interdisciplinary 
healthcare team (Alpert & Gatlin, 2015). 
Limitations of the Literature Review Process  
 Many studies stated that older adults living in long-term care facilities are at risk of 
adverse drug events due to polypharmacy (Charlesworth et al., 2015; Jokanovic et al., 2015).  
Before polypharmacy interventions, studies suggested there must be a consistent definition of 
polypharmacy (Jokanovic et al., 2015; Masnoon et al., 2017). 
Many studies offered interventions to reduce potentially inappropriate medications.  
Interventions achieved through validated tools can reduce inappropriate medications.  However, 
the literature presented little evidence about which tool is best suited in long term care and that 
nurses can use for medication reviews.  The research has limited information on how an 
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interdisciplinary team should use pharmacist reviews to identify inappropriate medications 
among older adults (Brown, 2016).  
Discussion  
Conclusion of findings.   Inconsistency of polypharmacy definitions created uncertainty 
about solving this problem of older adults with comorbidities.   The nature of polypharmacy can 
help drive interventions.  Potentially inappropriate medications increase older adults’ risk of 
polypharmacy.  When polypharmacy is present, a drug to drug interaction increases.  Drug to 
drug interaction can increase injury among older adults.  One way to reduce the use of 
potentially inappropriate medications, the implementation of a validated assessment tool should 
be considered.  Multiple validated assessment tools provided an intervention to reduce 
polypharmacy, such as BEERs Criteria, STOPP/START, or ARMOR.  The practice of 
completing medication reviews frequently is another strategy.  The validated tool that can 
accurately assist in providing medication reviews for old adults is the STOPP/START; the tool is 
a similarity of the BEERs Criteria, although it gives more information related to the 
physiological systems (Brown, 2016).   
Advantages and disadvantages of findings.  The benefit of the proposed intervention is 
that the START/STOPP tool is validated (Dagli & Sharma, 2014).  The STOPP/START tool will 
help assess the risk of polypharmacy in older adults (Dagli & Sharma, 2014).  Using the 
STOPP/START will help reduce unwarranted safety outcomes related to potentially 
inappropriate medications (Arnoldo et al., 2016).  In the literature, it asserts that a reduction in 
polypharmacy would reduce the cost of health care (Jokanovic et al., 2015).  The utilization of 
the STOPP/START tool significantly improves potentially inappropriate medications in older 
adults (O’Mahony et al., 2015). 
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The disadvantage of findings is that the literature does not explicitly state that nurses 
have used the STOPP/START tool in the past.  There is limited evidence found on nurses 
utilizing the tool in long-term care facilities; a provider usually uses the STOPP/START tool.  
Utilization of findings in practice change.  The facility Licensed Practical Nurse (LPN) 
and Registered Nurse (RN) received training to use the STOPP/START tool.  The 
STOPP/START tool utilized to complete a comprehensive medication review to decrease 
potentially inappropriate prescribing (Dagli, & Sharma, 2014).  The literature stated that the 
STOPP tool provides intervention related to duplication of drug class, interactions between 
drugs, drug-disease interactions, and medicine that may increase the resident risk of falling 
(Brown, 2016).  The START tool is combined and used with the STOPP tool.  However, the 
STOPP is more often used to recognize the use of inappropriate medications and the presentation 
of adverse drug events (Brown, 2016).  The START tool is used with the STOPP tool, guiding 
recommendations of medicines in older adults that may relate to a diagnosis (Brown, 2016).  The 
START tool recommends medications that should be considered in implementation to benefit 
older adults (Brown, 2016).  This validated tool helped nurses recognize the “warning signs" 
related to potentially inappropriate medications that may need observation (Brown, 2016). 
Summary  
 This chapter reported information on the literature review related to polypharmacy in 
older adults residing in long-term care facilities.  After reviewing the literature, the results 
showed that there was a need to reduce potentially inappropriate medications and polypharmacy 
in older adults.  The synthesis of the research showed that polypharmacy in older people results 
in an increased risk of drug events.  Due to the increase in drug events in older adults related to 
polypharmacy, there is an increased need to be seen by a provider driving the cost of healthcare 
POLYPHARMACY                                                                               22 
 
up.  The literature review showed that the implementation of a validated tool such as the 
STOPP/START tool could reduce polypharmacy and potentially inappropriate medications in 
older adults.   
  The implementation of the STOPP/START tool is in alignment with Triple Aim by 
improving the older adults' quality of care, improving older adults' health, and reducing the cost 
for health care.  The STOPP/START tool improves older adults' health by improving medication 
appropriateness and reducing adverse drug events, which will enhance patient safety. 
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Chapter Three:  Theory and Concept Model for Evidence-based Practice  
The theory is at the forefront of evidence-based practice.  The purpose of this chapter is 
to discuss the key concepts used in this project.  Besides, Lewin's change theory relates to a 
change of behavior in the implementation of a quality improvement project.  The Plan Do Study 
Act (PDSA) cycle provides an overview as it relates to a sequence of change through a process. 
Concept Analysis  
 The major concepts of this project are polypharmacy, older adults, adverse drug events, 
potentially inappropriate medication, potentially inappropriate prescribing, and medication 
review.  In this section, defined and discussed are the concepts.  
Polypharmacy.  According to Masnoon et al. (2017), there is no agreement on the 
definition for polypharmacy; definitions vary from numerical to descriptive.  Frequently defined 
as a numerical definition is polypharmacy (Masnoon et al., 2017).  After reviewing the literature, 
several articles defined polypharmacy as the use of five or more medications consumed by an 
individual (Alpert & Gatlin, 2015; Arnoldo et al., 2016; Brown, 2016; Charlesworth et al., 2015; 
Jokanovic et al., 2015; Masnoon et al., 2017; Morin et al., 2018). 
Older adults.  Older adults sometimes referred to as adults aged 65 years or older (Morin 
et al., 2018; O’Mahony et al., 2015).  At times, the terms elderly and aged were used instead of 
older adults (Alpert & Gatlin, 2015; Brown, 2016; Dagli & Sharma, 2014; O’Mahony et al., 
2015).  According to Wooten (2015), the older adult was distinguished by age, as 65-74 years 
old were considered early older adults, and those 75 years and older were considered late older 
adults.  This distinction is vital if conducting specific research or interventions (Wooten, 2015). 
Adverse drug events.  Adverse drug events (ADEs) happens when an individual obtains 
an injury as a result of an intervention related to medication (Alpert & Gatlin, 2015; Arnoldo et 
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al., 2016; Brown, 2016; Morin et al., 2018).  More than half of the adverse drug events that occur 
in older adults are preventable (Alpert & Gatlin, 2015). 
Potentially inappropriate medication.  Potentially inappropriate medication (PIM) is a 
medication that has the potential for harm where the risk outweighs the benefit for an individual 
(Brown, 2016; Dagli & Sharma, 2014; Masnoon et al., 2017).  Polypharmacy increases the 
chance of an individual taking inappropriate medications. 
Potentially inappropriate prescribing.    Potentially inappropriate prescribing increases 
the cost of health care (Jokanovic et al., 2015).  Potentially inappropriate prescribing (PIP) is a 
medication used in a situation in which the adverse drug events or risk dominates the benefit of 
the medication clinically; there may be safer alternatives for treatment (Jokanovic et al., 2015; 
Masnoon et al., 2017; O’Mahony et al., 2015). 
Medication review.  A medication review is the review of all medications taken by an 
individual, whether prescribed by or purchased over the counter (Alpert & Gatlin, 2015; Arnoldo 
et al., 2016; Brown, 2016).  Various health care professionals conduct medication reviews, 
including a nurse, nurse practitioner, physician assistant, medical doctor, and (or) a pharmacist 
(Alpert & Gatlin, 2015, Brown, 2016). 
Theoretical Framework  
 Naming the theory.   This DNP project modeled Lewin’s change theory.  A behavioral 
scientist developed the Lewin's change theory in the 1940s, Kurt Lewin (Bishop, 2018).  Lewin’s 
change theory intended to help implement change in the desired direction (Borkowski, 2016).  
Lewin’s change theory describes behavior related to change as the dynamic force that moves in 
opposing directions within an organization (Bishop, 2018).  The Lewin’s change theory has three 
stages within a process used to implement planned changes among an organization (Borkowski, 
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2016).  The three stages of Lewin’s change theory are unfreezing, change (sometimes referred to 
as moving), and refreezing (Bishop, 2018) (see Figure 1). 
Unfreezing is the process of interrupting and getting rid of old behavior patterns (Bishop, 
2018).  To establish unfreezing, driving forces must push direct behavior from existing situations 
(Bishop, 2018).  When there is effective communication about the need for change between 
managers and staff, unfreezing can take place or implemented in an organization (Borkowski, 
2016).  It is crucial for unfreezing in the organization to eliminate potential risks and behaviors 
that may affect the change.  The staff should understand that change is needed.  The second stage 
of Lewin’s change theory is a change or moving stage.  The stage of change is a process; this is 
when the change takes place (Bishop, 2018).  The stage of change is the process of changing 
thoughts or behavior, permitting individuals to shift to acceptable behaviors (Bishop, 2018).  The 
third stage of Lewin’s change theory is refreezing, which involves re-establishment of 
equilibrium and change, so that old behaviors do not return (Bishop, 2018). 
 A quality improvement project in a new community nursing team used Lewin’s change 
theory (Tinkler, Hoy, & Martin, 2014).  The framework improved how nurses complete bandage 
techniques on individuals with venous leg ulceration after implementation (Tinkler, Hoy, & 
Martin, 2014).  The Lewin’s change theory proposed to improve change among the nurses using 
the guidelines and protocol to complete compression bandaging (Tinkler, Hoy, & Martin, 2014).   
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Figure 1.  Lewin’s Change Theory 
Application to practice change.  Change is certain to take place in every organization; 
without change, habits develop.  The Lewin’s Change Theory supported the intervention for this 
DNP project implementation by initiating change among the nurses.  This framework used to 
implement the use of the STOPP/START tool among nurses in a long-term care facility.  
In stage one (unfreezing), the nurses were more willing to change their feelings, thoughts, 
and behavior about when and how medication review completion takes place among older adults.  
The nurses were encouraged to shift from completing medication reviews monthly to more 
frequently using a validated medication tool.  During the unfreezing stage, there may be many 
restraining forces that the nurses must overcome.  Some of the restraining forces might be the 
demand for workload and lack of time.   
In stage two (change), the STOPP/START tool was implemented in the long-term care 
facility for the nurses to use when completing medication reviews or reconciliation. 
In stage three (refreezing), the nurses would continue to use the STOPP/START tool to 
complete medication reviews, reducing polypharmacy, and potentially inappropriate medications 
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among older adults.  The nurses received support from managers until a change was complete.  
The STOPP/START tool would be implemented into policy, stimulating practice change. 
Evidence-Based Practice Change Model  
Plan Do Study Act.  Research and quality improvement (QI) were the driving forces of 
changes taking place in healthcare.  This quality improvement project implemented the Plan Do 
Study Act (PDSA) cycle.  Developed in the 1920s was the PDSA cycle was formerly known as 
the Demin Cycle (Crowfoot & Prasad, 2017).  The PDSA cycle is a continuous cycle of plan, do, 
study, act used to increase knowledge and improve a process within healthcare (Anderson, 
2018).  The PDSA cycle has elements of the cycle used for adjusting a process: Plan, Do, Study, 
Act.  
The PDSA cycle focuses on quality improvement in four steps that can repeat.  The first 
step of the PDSA cycle is the plan.  During the planning phase, the problem was determined.  
The planning phase involved identifying an area that needs to be improved and determining if it 
could benefit from quality improvement (Crowfoot & Prasad, 2017).  During the “do” step, 
implementation of changes takes place, whether they are unintended or unplanned outcomes 
(Crowfoot & Prasad, 2017).  The “study” step is sometimes called the check step.  Anderson 
(2018) states that the study step involved the evaluation of change, as well as data comparison to 
a prediction.  The “act” step is when adjustments take place; this determines whether the change 
was implemented or unused, causing the cycle to repeat (Anderson, 2018).   
Application to practice change.  The PDSA cycle implementation in this quality 
improvement project helped with making changes quickly and successfully (Anderson, 2018).  
This change cycle focused on the continuous improvement of the process (Crowfoot & Prasad, 
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2017).  The PDSA cycle helped reduce resistance when change begins in the long-term care 
facility.  Four stages of the PDSA cycle helped implement change (see Appendix C).   
Plan.  The plan involves understanding the current problem or situation.  The problem 
was polypharmacy among older adults.  The enforced change is a new policy that will 
incorporate the use of the STOPP/START tool for comprehensive medication reviews.  The 
development of the outcome or goal was to (a) train nurses about comprehensive medication 
reviews and (b) reduce polypharmacy and potentially inappropriate medications through using a 
validated tool (STOPP/START).  The DNP project lead used a data collection tool to obtain the 
patient's age, gender, total medications taking, and potentially inappropriate medications.  With 
the data, weekly chart reviews completed using the collection tool.  The nurse of the facility 
completed medication reconciliation for the older adults utilizing the STOPP/START tool 
medication orders are changed and transitions in care. 
Do.  Do involves the change being implemented and carried out on a small scale to test 
change.  The unexpected problems and results documented, explained what happened during the 
implementation of the plan. 
The nursing staff received education on medication reconciliation.  The STOPP/START 
tool provided for each LPN that conducts medication reconciliation at the site to use during 
reconciling medications.  There was an evaluation of the LPNs behaviors as it related to using 
the STOPP/START tool for medication reconciliation. 
Study.  The study involves reviewing the changes and outcomes and comparing the 
results or data to what is predicted or learned (Hunter, 2015).  Every week the results or data 
were reviewed.  
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Act.  The act involves what changes that should be made and the planning of the next 
change cycle (if needed), starting over with a plan based on the information obtained (Anderson, 
2018; Crowfoot & Prasad, 2017; Hunter, 2015).  The cycle was revised every two weeks based 
on the data collected and the needs of the site.  The site received recommendations for future 
modifications. 
Summary  
 Concepts are the terms or words that used to communicate an idea within a theory; the 
terms are usually broad (Butts & Rich, 2018).  Most concept terms have multiple definitions.  
There are several concept terms used in this project:  polypharmacy, older adults, adverse drug 
events, potentially inappropriate medication, potentially inappropriate prescribing, and 
medication review.  A change in behavior is needed to take place in the organization among the 
nurses before this quality improvement project implementation took place.  Lewin’s change 
theory is the chosen framework to be implemented.  The Lewin’s change theory will change 
behavior through unfreezing, moving, and refreezing, causing the driving forces to push the 
nurses toward change.  The nurses were more willing to complete medication reviews more often 
than once per month using a validated tool.  The Plan Do Study Act (PDSA) cycle supported the 
acceleration of the quality improvement project in reducing polypharmacy and potentially 
inappropriate medications.  The PDSA cycle is a continuous cycle that will be used for ongoing 
quality improvement to ensure the implementation of the new policy related to the nurses using 
the STOPP/START tool as part of medication reviews. 
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Chapter Four:  Pre-implementation Plan 
To implement a DNP project, it must have a comprehensive plan.   A pre-implementation 
plan is essential to have a successful quality improvement (QI) project.  During the pre-
implementation planning, the approval process from the institutional review board (IRB) began.  
This DNP polypharmacy project pre-implementation plan will be detailed in this chapter. 
Project Purpose 
The purpose of this Doctor of Nursing Practice (DNP) project was to decrease 
polypharmacy among older adults and to increase medication reconciliation.  The 
STOPP/START criteria, a validated tool, will identify inappropriate medications that contribute 
to polypharmacy.  The project site was a nonprofit organization in eastern, North Carolina.  It is 
an Intermediate Care Facility (ICF), which is a level of long-term care.  This DNP project aligns 
with a Triple AIM: reducing health care costs by reducing the number of inappropriate 
medications that contribute to polypharmacy. 
Project Management 
Organizational readiness for change.  According to the Chief Nursing Officer (CNO) 
and the Medical Consultant, the project site was ready for change.  For example, the CNO stated 
that there were multiple sites in which older adults consume numerous medications.  The CNO 
thought that some individuals received inappropriate medications.  The medical director of the 
project site agreed to be site champion to help change practice.  The Medical Consultant and 
CNO chose the STOPP/START criteria to reduce polypharmacy, healthcare cost, and improve 
care quality among patients at the facilities.  The clinical staff was reluctant to change due to the 
feeling of not completing all other daily duties.  Most clinical staff had longevity with the 
organization and were complacent with completing the task as trained initially. 
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Interprofessional collaboration.  In partnership with the medical director, the DNP 
student-led the project.  Other project team members were the Chief Executive Officer (CEO), 
CNO, DNP project faculty mentor, and facility Licensed Practical Nurses (LPNs) and Registered 
Nurse (RN) team leaders.  The CEO of the organization signed for approval of this quality 
improvement project.  The Medical Consultant was the site champion, who holds a master's 
degree in nursing (MSN-ANP) and provided polypharmacy knowledge to the project lead.  The 
CNO provided relevant knowledge about each site's needs related to polypharmacy, ensuring 
each LPN give recommendations to the provider.  The DNP project faculty mentor provided 
academic expertise and resources to help guide the project lead.  The DNP project team members 
worked together to improve polypharmacy in long-term care. 
Risk management assessment.  The Strength, Weakness, Opportunity, Threat (SWOT) 
Analysis assessed the risk management within this DNP project. 
Strength.  There are many strengths to this project.  One of the strengths was the project 
leader was an RN team leader at the project site.   Because of this experience, the project leader 
was aware of the organization’s needs to improve an individual’s quality of care.  Another 
strength is that the Medical Consultant (site champion) was responsible for policy 
implementation within the organization.  This factor made it easier to gain support for this DNP 
project.  The strength of the project included that there was a strong need to reduce 
polypharmacy in the elderly within long-term care facilities.  There was relevant information in 
the literature to support polypharmacy. 
 Weakness.  Time was a significant weakness in this project.  The facility LPN and RN 
team leaders may not have time to use the STOPP/START criteria due to other job 
responsibilities.  The timeframe of the project implementation included eight weeks, with an 
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evaluation of the Plan-Do-Study-Act (PDSA) cycle every two weeks.  There were knowledge 
gaps and inexperience among the LPN and RN team leaders.  Clinical staff might be resistant to 
the implementation of new strategies to complete medication reviews. 
 Opportunity.  An opportunity of this quality improvement project included that the 
project can be expanded and used within all the facilities of this non-profit organization.  This 
project also created educational opportunities for the nurses on a validated, evidence-based tool.  
The project would decrease polypharmacy among older adults in long-term care.  The project 
would improve patient health outcomes, potentially reducing the cost of care.  The project could 
be implemented as an organization-wide policy. 
 Threat.  Threats to project implementation were increased clinical staff workload.  If the 
clinical staff (LPN/RN team leaders) have more responsibilities to clients, it may affect 
medication reconciliation while using the STOPP/START criteria.  The clinical staff turnover 
rate was also a threat to this project.  Direct-care staff shortage could impose a threat also as the 
clinical staff may be needed more to assist with daily care. 
Organizational approval process.  The professional relationship with the project site 
occurred because the project leader was an RN team leader at the non-profit organization.  The 
method of gained organizational approval was the project leaders met with CNO to discuss 
polypharmacy in the organization and the purpose.  Then communication via email was 
completed with the Medical Consultant about the plans of the project with feedback about the 
best-validated tool to use.  The project stakeholders supported this project because there was a 
need for a decrease in polypharmacy in the long-term care facility.  The Medical Consultant 
communicated with the CEO about the project, plans, and timeline.  The final project approval 
was given by the Medical Consultant and the CEO of the organization to conduct it (see 
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Appendix D).  The project was approved through East Carolina University College of Nursing.  
If any changes occur during this project, the approval process would be revisited with both 
organizations to obtain supplementary approval. 
Information technology.  The project required minimal use of information technology to 
implement it.  The project used electronic mail for communication among stakeholders and 
clinical staff.  The electronic medical record (EMR) provided relevant data.  The EMR, Eclipse, 
is owned by the non-profit organization.  Other information technologies are Microsoft Office 
Word, Microsoft Office Excel, and Microsoft Office PowerPoint.  There will be no HIPPA 
violations because no patient identifiers will be obtained. 
Cost Analysis of Materials Needed for Project 
  DNP project implementation required a minimal cost.  The project cost included hard 
copy printing and employee snacks.  Project costs equaled less than $80 (see Appendix E).  The 
STOPP/START tool was printed as hard copies for the clinical staff at $0.13 per page.  There 
was a copy of the STOPP/START laminated for each facility use, costing $1.89 per page.  The 
DNP project lead completed prints and lamination at Staples.  There was no cost for the 
Microsoft PowerPoint presentation because the DNP project lead created it.  Snacks were 
available during medication reconciliation presentations. 
Plans for Institutional Review Board Approval 
The project site does not have an Institutional Review Board (IRB), but an internal 
organizational equivalent to the Ethics Committee and C-Team Risk Management.   The C-Team 
or Corporate Team consisted of the chief executive officer, chief operating officer, chief 
financial officer, and chief nursing officer.  The project lead contacted the Medical Consultant 
via electronic mail and obtained project approval once the project was confirmed beneficial to 
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the organization.  The project lead completed an Approval Process-Quality worksheet to submit 
to ECU IRB.  The DNP project lead completed the University IRB verification process.  The first 
step was completing the IRB QI/Program Evaluation Self-Certification Tool.  After obtaining 
approval from the DNP Faculty Lead, the tool was submitted online.  The project deemed to be 
QI; an immediate response was received stating that IRB review was not required.  An IRB letter 
was obtained on July 15, 2019, saying the project does not require IRB approval (see Appendix 
F).  The Social/Behavioral Research Investigators and Key Personnel course was completed via 
the Collaborative Institutional Training Initiative (CITI training) in February 2019. 
Plan for Project Evaluation 
Demographics.  The demographic information collected was age, gender, and ethnicity.  
The age reported as a mean and a range.  Gender and ethnicity reported through descriptive 
statistics, frequency.  A bar graph presented age data.  A pie chart indicated gender and ethnicity 
data. 
Outcome measurement.  This DNP project’s outcome measurement is to reduce 
polypharmacy and inappropriate medications in long-term care.  The outcome is to increase the 
use of STOPP/START by each LPN, increasing accurate medication reconciliation for each 
individual in the long-term care facility.  The project metric is an outcome measure related to 
patient outcomes.   
Instrument.  The project leader did not need to obtain permission to use the 
STOPP/START tool.  This project used Version 2.0 of the STOPP/START tool.  The 
STOPP/START tool has an attribution non-commercial 4.0 international license.  The 
STOPP/START can be shared or adapted if appropriate credit is given and not used for 
commercial purposes (O’Mahony et al., 2015).  The STOPP/START tool received validation by 
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an expert panel and Delphi consensus methodology (O’Mahony et al., 2015).  The validated tool 
has reliability, as there is evidence in which the instrument has effectively reduced potentially 
inappropriate medications in older adults (see Appendix G). 
Educational Tool.  The educational tool was developed in Microsoft Office PowerPoint, 
used to educate the clinical staff.  The tool was used by the project lead to inform the clinical 
team about medication reconciliation.  The educational tool defines medication reconciliation.  
The tool also explains why, when, who, and how medication reconciliation is completed. 
Data Collection tool.  The data collection tool was developed in Microsoft Office Excel 
spreadsheets by the project leader.  The tool was used by the project lead to obtain demographics 
(excluding patient identifying information), and the medication list from each chart (paper/EMR) 
assessed (see Appendix H). 
Data analysis.   Percentage of medication reconciliation were obtained three months 
before implementation from the EMR and some paper charts; June 2019 to August 2019.  Data 
was reviewed in a short period due to NC State Regulations to archive previous year information 
from the client’s chart after the annual individual program planning meeting each year.  Rate of 
medication reconciliation, the number of adults that had polypharmacy, and prescribed 
inappropriate medications will be reviewed to obtain data.  The percentage of pre-intervention 
and post-intervention were derived and compared.  There were no pre-existing benchmarks for 
this quality improvement project.  There was no current data found related to state and national 
benchmarks as it refers to polypharmacy.   Due to the lack of viable information, the national 
benchmarks related to reducing adverse drug events related to medications was archived in 2015 
(Office of Disease Prevention & Health Promotion [ODPHP], 2019) 
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Data management.  Data were managed by documenting in a Microsoft Office Excel 
Spreadsheet.  No patient identifiers were obtained from the EMR.  Any data collected was shared 
through the secure file system, Egnyte.  Egnyte allows data-sharing limited to stakeholders of the 
organization.  The data-share through Egnyte has a two-step verification system.  A secondary 
storage method was the project lead’s password-protected computer.  A flash drive was 
purchased to store data separate from the project lead’s password-protected, which was locked in 
a file cabinet for eight months.  All electronic mails were completed from the organization's 
electronic mail system with a privacy/confidentiality statement.  The EMR and paper charts 
provided relevant data.  The data collected for this quality improvement project was only stored 
on the flash drive and password-protected the computer from September 2019 to April 2020.  
When the project lead completed the DNP program, all files and data were deleted.   
Summary 
 The pre-implementation planning of the DNP project was a crucial stage completed 
before obtaining a waiver for QI and project implementation.  The project goal was to meet the 
Triple Aim objectives.  Project completion will increase medication reconciliation by nursing 
staff, which will reduce polypharmacy and healthcare costs.  Being able to increase medication 
reconciliation to at least 25% at the project site will improve the quality of care.  Strategically 
planning of this project took place with the stakeholder input.  The STOPP/START tool was 
available for use by the LPNs and RN team leaders before project implementation in September 
2019.  The data obtained during this project will be organized, then examined to show where 
barriers may exist. 
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Chapter Five:  Implementation Process 
The chapter describes the DNP project's implementation process.  This chapter also 
describes the project setting and participants.  During this chapter, discussion related to 
recruitment, implementation details, and project variation plans.  Recruitment of the participants 
will include in what dynamic the participant was involved in the project, and any barriers the 
participants may have.  The implementation details will describe how the plan for the project, 
emphasizing evaluation periods.  The PDSA cycle showed changes made during the project 
within the project variations plan.  The re-evaluation of the project was throughout eight weeks. 
Setting 
        This project implementation was in eastern North Carolina (NC).  The project site is a 
human service agency, which is a division providing service under the supervision of the 
department of health.  This site is a long-term care facility, which is an intermediate care facility 
(ICF) for adults with intellectual and (or) developmental disabilities.  It is part of an NC based 
non-profit organization 501(c-3).  The project site operates under federal regulations and 
standards with annual state surveys.  Project site funding source is Medicaid; all clients must be 
eligible or receive Medicaid.  The project goal was to reduce costs and improve the quality of 
care to the organization’s consumers.  The project designed to have a measurable impact on the 
clinical staff’s medication reviews.  
Participants 
        Project participants are the clinical staff that provides care to the individuals served at this 
organization.  The clinical staff consists of the facility licensed practical nurses (LPNs) and 
registered nurse (RN) team leaders.  Facility LPNs are responsible for the resident’s daily care, 
physician orders, order and receive medication, maintain the drug room, documents episodically 
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on all clients, schedule medical/dental appointments, and works under RN supervision.  RN team 
leaders supervise and train LPNs, attend annual team meetings and program planning, and make 
referrals to appropriate community resources as needed and during discharge planning.   
 The inclusion criteria are that participants must be either an LPN or an RN team leader, 
including the CNO and quality management nurse.  All LPNs employed within the organization 
at the two sites received education about medication reconciliation.  Project exclusion criteria of 
the project are any LPNs directly supervised by the DNP student. 
Recruitment 
        The QI project involved all RN team leaders and the LPNs employed at each of the two 
sites.  The two sites included in this project are each staffed by an RN team leader and a weekday 
LPN.  The change of process included the RN Team Leaders and LPNs.  The CNO explained the 
process to the RN team leaders, and the LPNs received information regarding the project from 
their supervising RN.  The internal stakeholders were thrilled about the possibility of reducing 
polypharmacy, which long-term could reduce health care costs.  The nursing staff was in 
agreeance to working with the DNP leader on this project since they felt there was a need to 
decrease polypharmacy while increasing medication reconciliation, utilizing an evidence-based 
tool.  However, the nursing staff, including the CNO, did not know the STOPP/START tool 
before project implementation.  The information documented on the tool was all new to each 
nursing staff.   The DNP leader shared information about the evidence-based use of the 
STOPP/START tool to reduce polypharmacy and potentially inappropriate medications.  The 
nursing staff perceived the project as being what could help reduce the number of medicines the 
older adults received or consumed daily.  The nursing staff were very excited and intrigued by 
the plan, given that there may be some barriers.  The barriers that the RN team leaders were 
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concerned about was time.  There was a concern if the LPN would have time to complete 
medication reconciliation using the evidence-based tool without lacking in other nursing 
responsibilities.  The use of the EHR would be a barrier to the project; at times, the server was 
down, making it hard to collect data.  The amendment would increase medication reconciliation, 
and the nursing staff would be able to identify potentially inappropriate medications that could 
contribute to polypharmacy.  The change was needed, and each staff was willing to participate.   
Implementation Process  
 Pre-Implementation.  Before implementing the project at the two sites, the DNP lead 
reviewed every chart at each facility.  The DNP lead determined which patients where 
considered older adults, 65 years, and older.  Each patient's medication list for the older adults 
was collected and determined how many medications were currently prescribed, including over 
the counter, topicals, and injections.  The information was input on an Excel spreadsheet and 
presented to the stakeholders at a C-Team meeting. 
 Educational Session.  The project involved the implementation of nursing education on 
medication reconciliation and the STOPP/START tool.  The project site champion emailed the 
DON regarding providing education to the nursing staff.  A PowerPoint presentation occurred at 
the monthly nursing staff meeting on the importance and process of completing medication 
reconciliation (see Appendix I).  During the educational session, it defined medication 
reconciliation and interventions to complete medication reconciliation.  There was an 
explanation of the STOPP/START tool in detail about how and when to use the tool.  The 
educational session provided an overview of the QI project that included an explanation of the 
process change and a new process of completing medication reconciliation with possible policy 
implementation. 
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 Project Implementation.  After the education of medication reconciliation and the use 
of the STOPP/START tool, the LPN used the evidence base tool when conducting medication 
reconciliation.  Medication reconciliation will take place among all adults 65 years and older 
when there is a change or new order and transitions in care.  The LPN will utilize the 
STOPP/START tool by body systems, obtaining evidence recommendation from the guideline, 
then providing the evidence-based recommendations to the provider. 
 Evaluation Method.  The DNP project leader completed chart reviews every week at 
each site to ensure that the LPNs were appropriately completing medication reconciliation on the 
older adults.  The chart reviews identified potentially inappropriate medications as it related to 
medication risks outweighing the benefits in older adults.  The chart reviews determined whether 
potentially inappropriate medications were started or changed according to the STOP/START 
guidelines.  Data collected from each chart review transferred on an Excel spreadsheet pre- and 
post-implementation.  The final chart review took place eight-weeks after implementation 
utilizing the PDSA cycle.  Upon completing chart reviews, more than 75% of the older adults at 
each site were prescribed and consuming potentially inappropriate medications.  The older adults 
were receiving the right treatment as it related to the START section of the tool.  However, some 
medications seemed to show duplication of drug class.  
 During the PDSA cycle, the DNP lead discovered that it was critical to document all 
potentially inappropriate prescriptions.  When the data was collected and analyzed, it was 
essential to display the total amount of potentially inappropriate medications, to allow the 
provider to make a judgment as to any changes needing to be made to the older adult medication 
regimen. Another cycle determined that the LPN at a site required to be educated frequently 
about medication reconciliation and the reasons.  The PowerPoint presentation was presented 
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initially before implementation and during implementation.  One of the sites was able to 
successfully implement the use of the STOPP/START tool, providing a recommendation to the 
provider based on evidence at each medication change or transition in care (See Appendix J). 
Plan Variation 
        The LPNs received education on medication reconciliation and the STOPP/START tool at a 
different time and date than that of the RN Team Leaders.  The LPNs were not able to attend the 
monthly nursing meeting due to location and time.  For the initial education session, four RN 
Team Leaders, one LPN, and the DON attended.  Unfortunately, one of the weekdays LPNs 
went out on maternity leave before implementation; back-up nursing staff participated in the 
educational session to continue the project plan.  There were two subsequent individual 
education sessions for the nursing staff working at the two sites.  There were subsequent 
individual education sessions completed at each project site with the individual LPNs that 
provided the care during the week. 
Summary 
        Weekly chart reviews occurred on adults 65 years and older in a long-term care facility.  
The goal of this QI project was to increase medication reconciliation.  A method used to 
accomplish the goal was the implementation of the STOPP/START tool, an evidence-based tool 
used to detect potentially inappropriate medications or prescribing omissions.  Additionally, it is 
essential to medication reconciliation to identify older adults at risk for polypharmacy and 
potentially inappropriate medication.  In completing this, a reduction of potentially inappropriate 
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Chapter Six:  Evaluation of the Practice Change Initiative 
Polypharmacy is most common among older adults.  The reduction of polypharmacy and 
inappropriate medications among older adults in long term care facilities is imperative to 
improving patient safety.  This chapter will discuss project results and areas of provider 
education that need enhancement.  This chapter will also examine the demographics of the 
participants, evaluation of the project outcomes, and significant findings related to the DNP QI 
project. 
Participant Demographics 
           During this DNP project implementation cycle, three LPNs and five RN team leaders, 
including the CNO and quality nurse, were trained to use the STOPP/START tool and applied 
the tool for completing medication reconciliation.  Demographics about the staff were obtained 
through verbal questions and conversation.  All the clinical staff received education on 
medication reconciliation and STOPP/START tool.  All the participants were females with 
different years of nursing expertise, ranging from 7 to 49 years.  Each nurse had varying levels of 
training, as it relates to education.   
 The provider, an adult-gerontology nurse practitioner (AGNP), was not included in this 
process of the quality improvement project.  The AGNP did not receive education on medication 
reconciliation or trained on the STOPP/START tool.  However, the AGNP was aware of the QI 
project being implemented. 
 The DNP project lead completed chart reviews on pre-implementation and post-
implementation.  There were no changes in patient demographics during those implementation 
phases.  The patient demographics were obtained through data collection using an Excel 
spreadsheet.  All the patients were 65 years and older, ranging from 66 to 85 years of age (M = 
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72).  Of the patients that were 65 years and older, 55% were male (n = 6), and the other 45% 
were female (n = 5) (see Figure 2).  Ethnicity was not studied; however, observation showed that 
73% of the participants were African American presented with polypharmacy (see Figure 3). 
 
Figure 2.  Demographics of Patients (Age/Gender) 
 
 
Figure 3.  Demographics of Patients (Ethnicity) 
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Intended Outcome(s)  
This DNP project short term outcomes were to introduce an evidence-based practice tool 
kit to complete medication reconciliation.  The DNP project leader projected that the occurrences 
of polypharmacy and inappropriate medication among adults that were ≥ 65 years would 
decrease with the use of the STOPP/START criteria.  
The intermediate project goal was for the clinical staff to change how and when they 
completed medication reconciliation.  The plan was to change the previous behaviors of the 
clinical team while adopting new ones.  The clinical would use the education and training related 
to the STOPP/START guidelines to complete accurate medication reconciliation. 
 The long-term goal was to increase comprehensive medication reconciliation after the 
nurses received educated on medication reconciliation.  The safety of older adults expected to 
increase after reducing polypharmacy through medication reconciliation. 
             Findings.  During the pre-implementation phase of the project, 100% of older adults (N 
= 11) in the long-term care facility recognized to have polypharmacy and potentially 
inappropriate medications.  Between the two long-term care facilities, eleven patients were ≥ 65 
years old at the pre-implementation phase of August 2019.  These eleven patients were 
prescribed more than five medications, with a least half of those specified potentially 
inappropriate medications per STOPP/START criteria (see Figure 4).   
 The project implementation phase took place over eight weeks from September 2019 to 
November 2019.  Two of the eleven patients diagnosed with gastroesophageal reflux disease 
(GERD) at one of the locations were discussed with the provider about being prescribed a proton 
pump inhibitor long-term without deprescribing and trying an H2 Blocker.  The STOPP/START 
tool recommends that a proton pump inhibitor dose should be reduced or discontinued if ordered 
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for maintenance or prophylactic treatment of GERD (O'Mahony et al., 2015).  The provider was 
unwilling to discontinue Nexium, a proton pump inhibitor due to ranitidine (H2 Blockers) recall.  
However, many other H2 Blockers are on the market, including famotidine and cimetidine.  It 
was evident that the provider needs more education on the utilization of evidence-based practice.  
By the end of post-implementation, there was one patient of the eleven that had a decrease in the 
number of medications ordered and potentially inappropriate medications (see Figure 5).  The 
post-implementation score (M =12.64, SD = 4.08). 
 
 
Figure 4.  Total number of medications with the number of potentially inappropriate 
medications. 
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Figure 5.  Total number of medications ordered Pre- & Post- Implementation. 
Summary 
In summary, 100% of the eleven patients aged ≥65 years deemed to have polypharmacy.  
After pre-implementation, all the patients (N = 11) were considered to have polypharmacy; 
therefore, many medications were identified as potentially inappropriate medications according 
to the STOPP/START guidelines.  The STOPP/START criteria can be effectively used to reduce 
potentially inappropriate medications in older adults that have polypharmacy to ensure patient 
safety.  Although the provider a non-participant, information was supplied to promote changes 
per the evidence-based tool.  Implementing this QI project in the future, the provider should be 
included in any education and training to increase the findings of the project.  
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Chapter Seven: Implications for Nursing Practice 
The American Association of Colleges of Nursing (AACN) defines the eight Essentials 
or core curriculum elements used to complete the Doctor of Nursing Practice (DNP) Program.  
The eight DNP Essentials aided to create and implement quality improvement for this project.  
The following chapter will define each essential as it aligned with this DNP project and 
implications for practice.   
Practice Implications 
             Essential I: Scientific underpinnings for practice.  The DNP Essentials I is aligned with 
how a DNP graduate uses the knowledge of science and theory as the foundation for advanced 
nursing practice.  According to AACN (2006), the DNP program prepares the graduate to 
integrate nursing science, utilize science-based theories and concepts, and to be able to establish 
and evaluate new practice initiatives.  Theory and concepts address the foundation of the DNP 
project. 
The QI project started with a systematic literature review that provided the background 
and significance of polypharmacy among older adults in long-term care facilities.  Kurt Lewin’s 
change theory is the theoretical framework for the project to implement change among the nurses 
conducting medication reconciliation.  The method supports changing behaviors through 
rejection and replacement of prior learning using an unfreezing-change-refreezing model.  The 
DNP project was completed using the Plan-Do-Study-Act (PDSA) cycle during the 
implementation of the project and to evaluate possible improvements due to time limitations.  
The PDSA cycle provided a platform for implementation and evaluation of the project in eight 
weeks.  A recommendation for the future would include the provider and the consultant 
pharmacist in the education of medication reconciliation utilizing an evidence-based tool. 
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             Essential II: Organization and systems leadership for quality improvement and 
systems thinking.  The DNP Essential II identifies how patient and healthcare outcomes show 
improvement through an organizational perspective.  The DNP prepared nurse should be able to 
provide quality of care and patient safety through initiatives of quality improvement integrating 
business, finance, economics, and health policy with adequate budgets and cost-analysis (AACN, 
2006).  According to AACN (2006), the DNP graduate should be able to create and evaluate 
strategies that can guide ethical dilemmas among patient care, research, and organizations.    
The DNP project focused on meeting the need of older adults in long-term care facilities.  
An assessment was completed of the organization to identify issues with plans to implement 
organization changes (policy); how the nurses should conduct medication reconciliation and 
reducing polypharmacy among the older adults.  The expenses related to the project are minimal, 
including providing copies of the STOPP/START tool.  The QI project was cost-effective, and 
the organization will not incur additional expenses when implemented as a standard policy.   
             Essential III: Clinical scholarship and analytical methods for EBP.  The third DNP 
Essential encompasses being able to translate research into practice.  According to AACN 
(2006), the DNP prepared nurse should be able to apply evidence-based knowledge from diverse 
sources and disciplines to solve practice problems and improve patient outcomes.  The DNP 
graduate should possess the capability of the appropriate use of information systems with 
research techniques to collect data, analyze data, analyze results, and identify gaps in evidence 
(AACN, 2006). 
The DNP graduate used the STOPP/START criteria, an evidence-based tool for 
medication reconciliation in long-term care facilities to reduce polypharmacy.  The DNP project 
was able to promote safe, timely, effective, and patient-centered care was utilizing a plan of 
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action (AACN, 2006).  Charts were reviewed before implementation to collect baseline data.  
The DNP graduate obtained outcome data regarding evidence-based practice and disseminated 
findings to the QI team to improve patient healthcare outcomes.  In the future, the 
interdisciplinary team approach needs to be implemented, including consultant pharmacy and 
provider. 
             Essential IV: Information systems/technology and patient care technology for the 
improvement and transformation of healthcare.  The understanding of information systems 
and patient care technology is a crucial component to be able to apply knowledge, manage 
information, and to support and improve patient care.  The DNP graduate should be proficient in 
the use of information technology so that quality improvement initiatives can occur during 
implementation.  The effectiveness of applying information technology/systems allows DNP 
graduates to be able to analyze, communicate, and evaluate healthcare and patient care (AACN, 
2006). 
  The DNP project was able to utilize healthcare technology, including the electronic 
health care record utilization, which allowed data to be collected; an excel spreadsheet helped to 
evaluate data.  The company-based email was a method to provide evidence-based education and 
communication with the chief executive officer, chief operating officer, chief financial officer, 
and chief nursing officer of the organization, as well as dissemination of outcomes.  The 
organizations’ electronic health record (EHR) provided pre-implementation and post-
implementation data.  The EHR was a valuable source for gathering data; however, there were 
days the server was not working, and data was not collected.  Since the EHR was not always a 
reliable source, one of the facilities utilized paper charts.  Information obtained from the EHR 
and paper chart was entered into an Excel spreadsheet to be analyzed.  The information provided 
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relevant details about the number of potentially inappropriate medications prescribed to each 
older adult.  The future recommendation is to obtain an electronic medication administration 
record with alerts of potentially inappropriate medications or adverse events. 
             Essential V: Healthcare policy for advocacy in healthcare.  In the fifth DNP 
Essential, DNP nurses are prepared to design, influence, and implement health care policies from 
organizational to governmental.  The DNP graduate will provide education to the stakeholders of 
organizations as it relates to nursing, health policy, and outcomes of patient care.  The DNP 
prepared nurse can provide advocation through the promotion of social justice and equity in 
healthcare (AACN, 2006).   
The DNP project completion is to implement a practice change in the organization.  The 
organization did not have an existing policy on medication reconciliation utilizing evidence-
based tools in a long-term care facility.  The stakeholders of the organization received education 
on the importance of medication reconciliation for older adults using evidence-based tools so 
that a policy can be implemented in the future to provide medication reconciliation. 
             Essential VI: Interprofessional collaboration for improving patient and population 
health outcomes.  DNP prepared nurses to provide an indispensable role in interprofessional 
collaboration, taking the leadership role as needed.  The AACN (2006) states that the graduate is 
prepared to utilize effective communication and collaborative skills to create and implement 
practice changes.  The DNP graduate possesses leadership qualities to be able to provide an 
analysis of practice or organizational issue that is complex (AACN, 2006). 
Implementation of the DNP project demonstrated a need to obtain input and cooperation 
from those on the interdisciplinary team of the organization.  The DNP project utilized 
interprofessional collaboration for improving patient outcomes with the nurses (LPNs and RNs), 
POLYPHARMACY                                                                               51 
 
an advanced practice nurse, and a medical director.  The DNP project lead assumed leadership of 
the team with effective communication and collaboration via telephone conferences and quality 
improvement meetings.  In the future, the organization should consider employing a DNP 
prepared nurse that has expertise in quality improvement to provide early changes. 
             Essential VII: Clinical prevention and population health for improving the nation’s 
health.  DNP Essential VII consists of health promotion, reducing risk, and preventing illness as 
it pertains to a group of individuals.  A shared characteristic classifies the group of individuals 
targeted in this project.  According to the AACN (2006), the DNP graduate possesses knowledge 
of clinical prevention and population health to implement activities that improve the health status 
of the United States.  The DNP graduate can analyze epidemiological data in the development, 
implementation, and evaluation of interventions to address gaps of care (AACN, 2006).   
The QI project's implications for practice were to provide education to the nurses about 
medication reconciliation and polypharmacy.  Epidemiological data were analyzed and provided 
pertinent information related to polypharmacy among older adults in long-term care facilities.  
The epidemiological data included age, gender, the total number of medications prescribed, and 
the amount of potentially inappropriate medicines based on the STOPP/START criteria of each 
individual.  Polypharmacy can have a problematic effect on aging adults; it is crucial to 
understand the benefits or risks of medication.  The DNP graduate can address gaps in care 
related to the process of completing medication reconciliation, reducing potential adverse events.  
The organization should consider policy implementation related medication reconciliation to 
reduce polypharmacy and adverse drug events. 
             Essential VIII: Advanced nursing practice.  DNP Essential VIII encompasses the 
competencies of foundational practice.   AACN (2006) states that the DNP program prepares the 
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graduate to have advanced knowledge and mastery in an area of nursing practice.  The DNP 
program prepares each graduate to be able to utilize nursing science and (or) other science to 
design, implement, and evaluate therapeutic interventions.  The DNP graduate provides 
evaluation among practice, organizational, population, fiscal, and policy issues through 
conceptual and analytical skills.  The graduate accomplishes high achievement by providing 
guidance and mentorship to other nurses, with the expectation of improving patient outcomes.  
DNP prepared nurses to have the knowledge and competency to be able to inform practices and 
address clinical issues among a variety of patient care settings (AACN, 2006).   
 This QI project took place in a long-term care facility; however, the lessons learned 
through this project could provide some benefit to other healthcare settings.  This competency 
accomplished the potential development of a new policy for completing medication 
reconciliation when changes are made to medication and during transitions of care.  Nurses can 
improve medication reconciliation in different settings if the knowledge of polypharmacy and its 
effects on older adults when disseminated.  The intervention of implementing the 
STOPP/START criteria could improve polypharmacy among older adults within other healthcare 
settings.  A standard is an evidence-based approach to medication reconciliation.  Employing 
DNP prepared nurses in the future will allow the organization to have a clinician that has the 
skillset to improve quality, as well as supporting other nursing to achieve excellence. 
Summary  
        The DNP Essentials is a well-defined guide used by advanced practice nursing programs to 
guide students and faculty with core concepts of the curriculum.  The DNP Essentials prepare 
nurses for a higher level of leadership.  Throughout this QI project, evidence-based data 
supported the quality improvement interventions of this project.  There was a collaboration with 
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the interdisciplinary team to provide education on medication reconciliation.  Information 
technology facilitated to obtain and analyze data related to polypharmacy.  This DNP project 
used the DNP Essentials during the planning, implementation, and outcomes.  The DNP 
Essentials was a valuable source for providing organizations with the capabilities of DNP 
prepared nurses.  Practice implications offer pertinent information to moving forward with this 
QI project and implementing it into the organization.  
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Chapter Eight: Final Conclusions 
This chapter is the conclusion of this DNP project, which provides a discussion of the 
clinical significance of this project with outcomes. There will be a thorough review of the 
findings, learned lessons, and project strengths and weaknesses.  An analysis provided how the 
use of the STOPP/START tool can be implemented in other settings.  The project benefits will 
be discussed as to how the cost is minimal and project recommendations that could impact a 
future change of practice.  
Significance of Findings  
          Initial findings from this project suggest that the use of the STOPP/START guidelines may 
decrease polypharmacy in older adults.  With the PDSA cycle, there were several educational 
sessions.  The education provided to the nurses did increase medication reconciliation as 
projected. 
  Although the Corporate or C-team, which consists of the chief executive officer, chief 
operating officer, chief financial officer, and the chief nursing officer, was interested in 
decreasing polypharmacy among the older adults.  Due to insufficient staffing, the clinical staff 
was concerned about time.  The clinical staff articulated that they would not have enough time to 
review the STOPP/START guidelines during each new medication order and at transitions of 
care.  The clinical staff had many other duties, including assisting with the client’s daily care at 
the times of short staffing.  The fears of the clinical staff were reduced minimally by explaining 
that the STOPP/START guidelines should be used for new medication orders.  An example was 
to ensure a medication did not cause drug-drug interaction or drug-disease interaction (such as a 
thiazide in a patient with a history of gout).  Time constraints were consistently the issue.  Being 
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that the staff was concerned about the time, it was apparent that the staff were not likely to 
complete medication reconciliation utilizing the STOPP/START guidelines. 
 The patients were impacted the most through the clinical staff, changing their behaviors 
in completing medication reconciliation.   The patients’ safety is affected by medication 
reconciliation.  Medication reconciliation lessens the chance of (1) discrepancies in a patient's 
drug list and (2) the number of adverse drug events.  The STOPP/START guidelines were simple 
to teach the staff and were free, other than the cost of printing.  The clinical staff received 
evidence-based printed information related to older adult prescriptions.  Medication 
reconciliation provides an accurate list of patient’s medications; any age or population can 
benefit.  In return, this suggests that this project can be translated into other long-term care 
settings and primary care as well as hospitals.   
Project Strengths and Weaknesses 
          This DNP project was challenging to implement.  The strengths of this DNP project were 
that the project was accepted and supported by the site clinical staff.  The clinical staff had not 
been involved in a QI project, but they were eager to learn about medication reconciliation and 
the STOPP/START tool.  By utilizing the STOPP/START tool without permission allows 
different health care settings to adapt it.  The project was economical to implement, with no 
incurred cost for the project sites.  If the organization adopts the project, minus the cost for the 
snacks provided, the cost should be minimal as printing can take place on-site. 
 Weaknesses of this project included the project sites were small, with a minimal number 
of adults sixty-five years or older to use the STOPP/START tool to complete medication 
reconciliation.  Of the 30 patients between the two sites, 37% were 65 years and older during the 
implementation phase.  The provider was absent at all education sessions.  If the provider 
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participated in the QI project during planning, this could have possibly increased the team 
approach and increased a reduction of potentially inappropriate medications. 
Project Limitations 
          The limitations of this DNP project included time constraints.  The project was limited to 
an eight-week implementation period.  The provider was not educated on the STOPP/START 
tool, using evidence-based data to reduce polypharmacy, affecting limitations to changes.  
Considering that the project sites were not entirely electronic, at times, not every medication 
order was recorded in the electronic health record.  The DNP project lead reviewed paper charts 
to obtain medication data.  At one of the sites, due to the limited staff time at the facility with the 
high demand for work, the tool was not utilized consistently. 
Project Benefits 
          There were many benefits of this QI project at a long-term care facility.  The clinical staff 
learned that medication reconciliation completion is more than once a month.  The clinical staff 
learned that medication reconciliation is completed at the time a new medication is ordered and 
change or transitions in care, including admissions and discharges. 
 The clinical staff is essential to prevent polypharmacy through medication reconciliation.  
Providing the clinical team with an evidence-based tool and guidelines to complete medication 
reconciliation will improve the care and safety of patients.  The cost of healthcare will decrease 
due to reducing polypharmacy, which reduces the possibility of an adverse drug reaction.  In 
return, the Centers for Medicare and Medicaid Services (CMS) will spend less on preventable 
adverse drug events.  As a result, there will be less money lost by the long-term facilities related 
to non-payment of CMS due to requiring a higher level of care services at a hospital for an 
unknown time-period (hospital stay).  
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Practice Recommendations 
          Following this quality improvement project, project recommendations include an 
organizational change.  All long-term care facilities should have an organizational policy in 
which medication reconciliation completion occurs in detail.  The change should consist of a 
procedure in which the nurses are required to use an evidence-based tool to achieve medication 
reconciliation.  The policy should provide details with what, why, who, when, and how 
medication reconciliation and procedures should be performed.  The what of the policy will 
define medication reconciliation.  The why of the policy will describe why the completion of 
medication reconciliation is relevant- patient safety and reduce polypharmacy.  The who of the 
policy will state that the LPN or RN completes medication reconciliation.  The when of the 
policy will state that completion of medication reconciliation takes place when there is a new 
medication order or transitions of care during admission or discharge.  The process of 
completing how medication reconciliation within the procedure includes (1) LPN or RN will 
verify the medication by comparing the drug name, route, dosage, and frequency according to 
medication history or list and (2) the medication will then be clarified by comparing to 
medication orders.  During the reconciliation phase, the clinical staff will use the 
STOPP/START tool to determine if any medications may be inappropriate for the older patient 
and suggest recommendations to the provider.  The policy should include continuous clinical 
staff education on medication reconciliation. 
 Adopting the use of the STOPP/START guidelines can be optional during medication 
reconciliation by the nurses or clinical staff.  The organization can choose another evidence-
based tool to help decrease adverse drug events related to polypharmacy, including the BEERs 
criteria.  Providers should understand why an evidence-based tool is used to help decrease drug-
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drug or drug-disease interactions, but it does not take the place of their clinical judgment or 
knowledge.  The provider should be made aware of each drug that a patient may be consuming 
that is potentially inappropriate and can cause harm. 
Final Summary 
         Polypharmacy is a relevant issue in long-term care facilities, affecting those that are sixty-
five years of age and older.  Polypharmacy in this population is increasingly rising, which, in 
return, increases older adults' need for care.  Increased morbidity, adverse drug events, or even 
mortality, can be an effect of polypharmacy, raising patient safety issues. 
 This DNP project implemented the use of the STOPP/START criteria to reduce 
polypharmacy among those that sixty-five years and older in long-term care, intermediate care 
facility for developmentally disabled adults in eastern NC.  The project was challenging, 
although inexpensive to implement.  The project did have limitations with time but was able to 
be completed as scheduled with minimal modifications. 
 The implementation of this QI project helped to implement evidence-based proposals into 
best practice and polypharmacy implications.  Providing nurses with education on medication 
reconciliation helped to close the gap between knowledge and evidence-based nursing practice.  
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older patients: A 
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Level V That communicating with 
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drugs helps with 
handling issues 
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To ensure that approaches or 
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Appendix B 
Flow Diagram of Study Selection 
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APPENDIX E 




LINE ITEM UNIT COST QUANTITY TOTAL 
Educational  
   
Printing and Photocopying $0.13  30 $3.90  
Laminating (evidence-based tool) $1.89  20 $37.80  
Educational Seminar Snacks 
   
Water (24 pack) $3.98  1 $3.98  
Fruit Tray $25.99  1 $25.99  
Granola Bars (6 pack) $2.98  2 $5.96  
Supplies 
   













Screening Tool of Older Persons’ Prescriptions (STOPP) 
Indication of Medication 
Drug prescribed without evidence-based 
indication 
STOP 
Drug prescribed beyond the recommended 
duration, where treatment duration is well 
defined 
STOP 
Duplicate drug class STOPP: Utilize single drug, before considering a 
new drug/agent 
Cardiovascular System 
Heart failure with normal systolic ventricular 
function 
STOP Digoxin- no evidence of benefit 
New York Heart Association (NYHA) Class III or IV 
heart failure 
STOP Verapamil or Diltiazem- may worsen heart 
failure 
Beta-blocker in combination with Verapamil or 
Diltiazem  
STOP one Verapamil or Diltiazem- risk of heart 
block 
Beta-blocker with bradycardia (< 50/min), type II 
heart block or complete heart block 
STOP- risk of complete heart block, asystole 
Amiodarone as first-line antiarrhythmic therapy 
in supraventricular tachyarrhythmias 
STOP- higher risk of side-effects than beta-
blockers, digoxin, verapamil, or diltiazem 
Loop diuretic as first-line treatment for 
hypertension  
STOP safer, more effective alternatives available 
Loop diuretic for dependent ankle edema 
without clinical, biochemical evidence or 
radiological evidence of heart failure, liver failure, 
nephrotic syndrome, or renal failure  
STOP- leg elevation and /or compression 
stockings usually more appropriate 
Thiazide diuretic with current significant 
hypokalemia (serum K+ < 3.0 mmol/l), 
hyponatremia (serum Na+ < 130 mmol/l) 
hypercalcemia (corrected serum calcium > 2.65 
mmol/l) or with a history of gout  
STOP- hypokalemia, hyponatremia, 
hypercalcemia, and gout can be precipitated by 
thiazide diuretic 
Loop diuretic for treatment of hypertension with 
concurrent urinary incontinence  
STOP- may exacerbate incontinence 
Centrally acting antihypertensives (methyldopa, 
clonidine, moxonidine, rilmenidine, guanfacine) 
STOP- unless clear intolerance of, or lack of 
efficacy with, other antihypertensives (centrally 
acting antihypertensives are generally less 
tolerated by older people than younger people) 
ACE inhibitors or Angiotensin Receptor Blockers 
in patients with hyperkalemia 
STOP 
Aldosterone antagonists (spironolactone, 
eplerenone) with concurrent potassium 
conserving drugs (ACEI’s, ARB’s, amiloride, 
triamterene) without monitoring of serum 
potassium  
STOP- risk of dangerous hyperkalemia > 6.0 
mmol/l; or serum K should be monitored six 
months 
POLYPHARMACY                                                                               72 
 
Phosphodiesterase type-5 inhibitors (sildenafil, 
tadalafil, vardenafil) in severe heart failure 
characterized by hypotension (systolic BP < 90 
mmHg), or concurrent nitrate therapy for angina  
STOP- risk of cardiovascular collapse 
Antiplatelet/Anticoagulant Drugs 
Long-term aspirin at doses greater than 160mg 
per day  
STOP- increased risk of bleeding, no evidence for 
increased efficacy 
Aspirin with a history of peptic ulcer disease 
without concomitant Proton Pump Inhibitor  
STOP- risk of recurrent peptic ulcer 
Aspirin, clopidogrel, dipyridamole, vitamin K 
antagonists, direct thrombin inhibitors or factor 
Xa inhibitors with concurrent significant bleeding 
risk (severe uncontrolled hypertension, bleeding 
diathesis, recent non-trivial spontaneous 
bleeding)   
STOP- high risk of bleeding 
Aspirin plus clopidogrel as secondary stroke 
prevention, unless the patient has a coronary 
stent(s) inserted in the previous 12 months or 
concurrent acute coronary syndrome or has a 
high grade symptomatic carotid arterial stenosis 
STOP- no evidence of added benefit over 
clopidogrel monotherapy 
Aspirin in combination with vitamin K antagonist, 
direct thrombin inhibitor or factor Xa inhibitors in 
patients with Chronic A. Fib 
STOP- no added benefit from aspirin 
Antiplatelet agents with vitamin K antagonist, 
direct thrombin inhibitor or factor Xa inhibitors in 
patients with stable coronary, cerebrovascular or 
peripheral arterial disease  
STOP- no added benefit from dual therapy 
Ticlopidine in any circumstances  STOP- clopidogrel and prasugrel have similar 
efficacy, stronger evidence, and fewer side-
effects 
Vitamin K antagonist, direct thrombin inhibitor or 
factor Xa inhibitors for first deep venous 
thrombosis without continuing provoking risk 
factors (thrombophilia) for > 6 months 
STOP- no proven added benefit 
Vitamin K antagonist, direct thrombin inhibitor or 
factor Xa inhibitors for first pulmonary embolus 
without continuing provoking risk factors 
(thrombophilia) for > 12 months 
STOP- no proven added benefit 
NSAID and vitamin K antagonist, direct thrombin 
inhibitor or factor Xa inhibitors in combination 
STOP- risk of major gastrointestinal bleeding 
NSAID with concurrent antiplatelet agent(s) 
without PPI prophylaxis 
STOP- increased risk of peptic ulcer disease 
Central Nervous System and Psychotropic Drugs 
Tricyclic Antidepressants (TCAs) with dementia, 
narrow-angle glaucoma, cardiac conduction 
abnormalities, prostatism, or history of urinary 
retention 
STOP- risk of worsening these conditions 
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Initiation of Tricyclic Antidepressants (TCAs) as 
first-line antidepressant treatment  
STOP- higher risk of adverse drug reactions with 
TCAs than with SSRIs or SNRIs 
Neuroleptics with moderate-marked 
antimuscarinic/anticholinergic effects 
(chlorpromazine, clozapine, flupenthixol, 
fluphenazine, pipotiazine, promazine, 
zuclopenthixol) with a history of prostatism or 
previous urinary retention  
STOP- high risk of urinary retention 
Selective serotonin re-uptake inhibitors (SSRI’s) 
with current or recent significant hyponatremia 
(Na+ < 130)  
STOP- risk of exacerbating or precipitating 
hyponatremia). 
Benzodiazepines for ≥ four weeks STOP- no indication for longer treatment; risk of 
prolonged sedation, confusion, impaired balance, 
falls, road traffic accidents; wean gradually to 
reduce withdrawal 
Antipsychotics (except quetiapine or clozapine) in 
those with parkinsonism or Lewy Body Disease 
STOP- risk of severe extra-pyramidal symptoms 
Anticholinergics/antimuscarinics to treat extra-
pyramidal side-effects of neuroleptic medications  
STOP- risk of anticholinergic toxicity 
Anticholinergics/antimuscarinics in patients with 
delirium or dementia  
STOP- risk of exacerbation of cognitive 
impairment 
Neuroleptic antipsychotic in patients with 
behavioral and psychological symptoms of 
dementia (BPSD) 
STOP- unless symptoms are severe and other 
non-pharmacological treatments have failed 
(increased risk of stroke) 
Neuroleptics as hypnotics, unless sleep disorder 
is due to psychosis or dementia 
STOP- risk of confusion, hypotension, extra-
pyramidal side effects falls 
Acetylcholinesterase inhibitors with a known 
history of persistent bradycardia (< 60 
beats/min.), heart block or recurrent unexplained 
syncope or concurrent treatment with drugs that 
reduce heart rate (beta-blockers, digoxin, 
diltiazem, verapamil) 
STOP- risk of cardiac conduction failure, syncope, 
and injury 
Phenothiazines as first-line treatment (sedative) STOP- safer and more efficacious alternatives 
exist 
Levodopa or Dopamine agonists for benign 
essential tremor  
STOP- no evidence of efficacy 
First-generation antihistamines  STOP- safer antihistamines available 
Renal System 
"the following drugs are potentially inappropriate in older people with acute or chronic kidney 
disease with renal function below particular levels of eGFR." 
Digoxin at a long-term dose greater than 
125mcg/day, if eGFR < 30 ml 
STOP- risk of digoxin toxicity if plasma levels not 
measured 
Direct thrombin inhibitors (dabigatran), if eGFR < 
30 ml 
STOP- risk of bleeding 
Factor Xa inhibitors (rivaroxaban, apixaban) if 
eGFR < 15 ml 
STOP- risk of bleeding 
NSAID’s, if eGFR < 50 ml STOP- risk of deterioration in renal function 
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Colchicine, if eGFR < 10 ml STOP- risk of colchicine toxicity 
Metformin, if eGFR < 30 ml STOP- risk of lactic acidosis 
Gastrointestinal System 
Prochlorperazine or metoclopramide with 
Parkinsonism  
STOP- risk of exacerbating Parkinsonian 
symptoms 
PPI for uncomplicated peptic ulcer disease or 
erosive peptic esophagitis at full therapeutic 
dosage for > 8 weeks  
STOP- or reduce dosage 
Drugs likely to cause constipation 
(antimuscarinic/anticholinergic drugs, oral iron, 
opioids, verapamil, aluminum antacids) in 
patients with chronic constipation where non-
constipating alternatives are available 
STOP- risk of exacerbation of constipation 
Oral elemental iron doses greater than 200 mg 
daily 
STOP- no evidence of enhanced iron absorption 
Respiratory System 
Theophylline as monotherapy for COPD  STOP- safer, more effective alternative; risk of 
adverse effects due to narrow therapeutic index 
Systemic corticosteroids instead of inhaled 
corticosteroids for maintenance therapy in 
moderate-severe COPD  
STOP- unnecessary exposure to long-term side-
effects of systemic corticosteroids and effective 
inhaled therapies are available 
Anti-muscarinic bronchodilators (ipratropium, 
tiotropium) with a history of narrow-angle 
glaucoma or bladder outflow obstruction 
STOP- may exacerbate glaucoma; may cause 
urinary retention 
Non-selective beta-blocker (whether oral or 
topical for glaucoma) with a history of asthma 
requiring treatment 
STOP- risk of increased bronchospasm 
Benzodiazepines with acute or chronic 
respiratory failure  
STOP- risk of exacerbation of respiratory failure 
Musculoskeletal System 
Non-steroidal anti-inflammatory drug (NSAID) 
other than COX-2 selective agents with history of 
peptic ulcer disease or gastrointestinal bleeding, 
unless with concurrent PPI or H2 antagonist  
STOP- risk of peptic ulcer relapse 
NSAID with severe hypertension or severe heart 
failure  
STOP- risk of exacerbation of hypertension; risk 
of exacerbation of heart failure 
Long-term use of NSAID (>3 months) for 
symptom relief of osteoarthritis pain where 
Acetaminophen has not been tried  
STOP- simple analgesics preferable and usually as 
effective for pain relief 
Long-term corticosteroids (>3 months) as 
monotherapy for rheumatoid arthritis  
STOP- risk of systemic corticosteroid side-effects 
Corticosteroids for osteoarthritis  STOP- risk of systemic corticosteroid side-effects 
Long-term NSAID or colchicine (>3 months) for 
chronic treatment of gout where there is no 
contraindication to a xanthine-oxidase inhibitor 
(allopurinol) 
STOP 
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COX-2 selective NSAIDs with concurrent 
cardiovascular disease  
STOP- increased risk of myocardial infarction and 
stroke 
NSAID with concurrent corticosteroids without 
Proton Pump Inhibitor prophylaxis  
STOP- increased risk of peptic ulcer disease 
Oral bisphosphonates in patients with a current 
or recent history of upper gastrointestinal disease 
(dysphagia, esophagitis, gastritis, duodenitis, or 
peptic ulcer disease, or upper gastrointestinal 
bleeding   
STOP- risk of relapse/exacerbation of esophagitis, 
esophageal ulcer, esophageal stricture 
Urogenital System 
Antimuscarinic drugs with dementia, or chronic 
cognitive impairment, or narrow-angle glaucoma, 
or chronic prostatism  
STOP- risk of increased confusion, agitation; risk 
of acute exacerbation of glaucoma; risk of urinary 
retention 
Selective alpha-1 selective alpha-blockers in 
those with symptomatic orthostatic hypotension 
or micturition syncope 
STOP- risk of precipitating recurrent syncope 
Endocrine System 
Sulfonylureas with a long duration of action 
(Glyburide, chlorpropamide, glimepiride) with 
type 2 diabetes mellitus  
STOP- risk of prolonged hypoglycemia 
Thiazolidinediones (rosiglitazone, pioglitazone) in 
patients with heart failure  
STOP- risk of exacerbation of heart failure 
Beta-blockers in diabetes mellitus with frequent 
hypoglycemic episodes  
STOP- risk of suppressing hypoglycemic 
symptoms 
Estrogens with a history of breast cancer or 
venous thromboembolism 
STOP- increased risk of recurrence 
Oral estrogens without progestogen in patients 
with intact uterus 
STOP- risk of endometrial cancer 
Androgens (male sex hormones) in the absence 
of primary or secondary hypogonadism  
STOP- risk of androgen toxicity; no proven 
benefit outside of the hypogonadism indication 
Drugs that predictably increase the risk of falls in older people 
Benzodiazepines STOP- sedative, may cause reduced sensorium, 
impair balance 
Neuroleptic drugs STOP- may cause gait dyspraxia, Parkinsonism 
Vasodilator drugs (alpha-1 receptor blockers, 
calcium channel blockers, long-acting nitrates, 
ACE inhibitors, angiotensin I receptor blockers) 
with persistent postural hypotension  
STOP- risk of syncope, falls 
Hypnotic Z-drugs (zopiclone, zolpidem, zaleplon)  STOP- may cause protracted daytime sedation, 
ataxia 
Analgesic Drugs  
Use of oral or transdermal strong opioids 
(morphine, oxycodone, fentanyl, buprenorphine, 
diamorphine, methadone, tramadol, pethidine, 
pentazocine) as first-line therapy for mild pain 
STOP 
Use of regular opioids without concomitant 
laxative  
STOP- risk of severe constipation 
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Long-acting opioids without short-acting opioids 
for break-through pain  
STOP- risk of persistence of severe pain 
Antimuscarinic/Anticholinergic Drug Burden 
Concomitant use of two or more drugs with 
antimuscarinic/anticholinergic properties 
(bladder antispasmodics, intestinal 
antispasmodics, tricyclic antidepressants, first-
generation antihistamines) 
STOP- risk of increased 
antimuscarinic/anticholinergic toxicity 
 
Screening Tool to Alert to Right Treatment (START) 
Cardiovascular System 
Vitamin K antagonists or direct thrombin 
inhibitors or factor Xa inhibitors in the presence 
of Chronic Atrial Fibrillation 
START 
Aspirin (75-160 mg Daily) in the presence of 
chronic atrial fibrillation, where the above is 
contraindicated 
START 
Antiplatelet therapy with a history of coronary, 
cerebral or peripheral vascular disease 
START 
Antihypertensive therapy where systolic blood 
pressure consistently > 160 mmHg and/or 
diastolic blood pressure consistently >90 mmHg; 
if systolic blood pressure > 140 mmHg and /or 
diastolic blood pressure > 90 mmHg, if diabetic 
START 
Statin therapy with history of coronary, cerebral 
or peripheral vascular disease, unless the 
patient’s status is end-of-life or age is > 85 years 
START 
Angiotensin-Converting Enzyme (ACE) inhibitor 
with systolic heart failure and/or coronary artery 
disease 
START 
Beta-blocker with ischemic heart disease START 




Regular inhaled B2 agonist or antimuscarinic 
bronchodilator (ipratropium, tiotropium) for mild 
to moderate asthma or COPD 
START 
Regular inhaled corticosteroid for moderate-
severe asthma or COPD, where FEV1 <50% of 
predicted value and repeated exacerbations 
requiring treatment with oral corticosteroids 
START 
Home continuous oxygen with documented 
chronic hypoxemia (O2 Sats <89%) 
START 
Central Nervous System & Eyes 
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L-DOPA or a dopamine agonist in idiopathic 
Parkinson’s disease with functional impairment 
and resultant disability 
START 
Non-TCA antidepressant drug in the presence of 
persistent major depressive symptoms 
START 
Acetylcholinesterase inhibitor (donepezil, 
rivastigmine, galantamine) for mild-moderate 
Alzheimer’s dementia or Lewy Body dementia 
(rivastigmine) 
START 
Topical prostaglandin, prostamide or beta-
blocker for primary open-angle glaucoma 
START 
Selective serotonin reuptake inhibitor (or SNRI or 
pregabalin if SSRI contraindicated) for persistent 
severe anxiety that interferes with independent 
functioning 
START 
Dopamine agonist (ropinirole, pramipexole, 
rotigotine) for Restless Legs Syndrome, once iron 




Proton Pump Inhibitor with severe 
gastroesophageal reflux disease or peptic 
stricture requiring dilatation 
START 




Disease-modifying anti-rheumatic drug (DMARD) 
with active, disabling rheumatoid disease 
START 
Bisphosphonates and vitamin D and calcium in 
patients taking long-term systemic corticosteroid 
therapy and/or BMD T-scores more than -2.5 in 
multiple sites 
START 
Vitamin D and calcium supplement in patients 
with known osteoporosis and/or previous 
fragility fracture(s) 
START 
Bone anti-resorptive or anabolic therapy 
(bisphosphonate, denosumab) in patients with 
documented osteoporosis, where no 
pharmacological or clinical status 
contraindication exists and/or previous history of 
fragility fracture(s) 
START 
Vitamin D supplements in older people who are 
housebound or experiencing falls or with 
osteopenia 
START 
Xanthine-oxidase inhibitors (allopurinol) with a 
history of recurrent episodes of gout 
START 
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ACE inhibitor or Angiotensin Receptor Blocker in 
Diabetes with evidence of renal disease (dipstick 
proteinuria or microalbuminuria >30mg/24 




Alpha-1 receptor blocker with symptomatic 
prostatism, where prostatectomy is not 
considered necessary 
START 
5-alpha-reductase inhibitor with symptomatic 
prostatism, where prostatectomy is not 
considered necessary 
START 
Topical vaginal estrogen or vaginal estrogen 
pessary for symptomatic atrophic vaginitis 
START 
Analgesics 
High-potency opioids in moderate-severe pain, 
where Acetaminophen, NSAIDs or low-potency 
opioids are not appropriate to the pain severity 
or have been ineffective 
START 
Laxatives in patients receiving opioids regularly START 
Vaccines 
Seasonal trivalent influenza vaccine annually START 
Pneumococcal vaccine at least once after age 65 START 
 
Adapted from O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & 
Gallagher, P. (2015;2014). STOPP/START criteria for potentially inappropriate prescribing in 












Total # of 
medications
Total # of Potentially 
Inappropriate Medications 
(Use STOPP criteria)
Potentially Inappropriate Medications (Name Drug) Interventions 




Use instructions on the next page
In Column F, record the number of potential inappropriate medications according to the STOPP criteria
In Column G, record the name of the potentially inapporpriate drugs
Intervention Codes
In Column H, determine interventions using codes. { 1- Discontinue Drug; 2- Add drug; 3- Change dose/interval; 4- Change duration; 5-Change from PRN to Scheduled; 6- Change 
from Scheduled to PRN}
Instructions
Purpose: To screen the clients within the facility for polypharmacy (5 or more prescribed drugs) and potentially inappropropriate medications (according to the STOPP criteria)
In Column A, assign a number to each client screened (Ex: Pt: 1, 2, 3, etc)
In Column B, please identify client gender (Male/Female)
In Colunm D, please record client age
In Column E, record the total number of medictations taken by the client












 Define Medication Reconciliation.
 Statistics of Medication Reconciliation.
 Identify reasons for Medication Reconciliation.
 Who completes Medication Reconciliation?
 When Medication Reconciliation is completed?





 82% of adults in the US take one medication and 
another 29% take 5 or more medications
 Annually there are nearly 1.3 million ER visits and 
350,000 hospitalizations related to adverse drug events





 In the US adverse drug reaction (ADR) is the 6th leading 
cause of death.
 ADR increases with age.
 More than a 20% chance of having an ADR
 Older adults have about 10% risk of being hospitalized 







 Medication Reconciliation is a complex process.
 According to Institute for Healthcare Improvement,“ 
medication reconciliation is the process of creating the 
most accurate list possible of all medications a patient 
is taking; including drug name, dosage, frequency, and 
route.”
(Gooen, 2017; IHI, 2019)
 




 Avoid Medication Errors
 Omissions 
 Duplications
 Dosing errors 
 Drug interactions
 Reduces polypharmacy in patients
 Improve Patient Outcomes
 Improve Patient Safety
 Reduce Health Care Cost
(Gooen, 2017; Molokhia & Majeed, 2017)
 





• Behavioral Health Care National Patient Safety 
Goal effective January 2019
• Goal 3:  Improve the safety of using medications
• Making medication reconciliation an important safety 
issues for the individual we serve
• Maintain and Communicate accurate medication 
information for the individual served 
The Joint Commission







 requires a team approach
 a shared responsibility among the healthcare 
providers
 Nurses- LPN, RN
 Providers- Physicians, NP
 Pharmacists








 Medication Review/Reconciliation should be completed
 At the time in which new medication orders are written
 At each patient transition of care
** With every patient encounter**










There are many tools that can be used to complete 
medication reconciliation:
 Electronic Health Record (EHR)
 BEERs Criteria
 Assess, Review, Minimize, Optimize and Reassess
 STOPP/START Criteria




 Utilize the Screening Tool of Older Person’s 
Prescriptions (STOPP)/ Screening Tool to Alert Doctor 
of Right Treatment
 Used for older adults (65 years and older)
 Identify potentially inappropriate medications or medication 
combination







Don’t forget to compare the over-the counter 









(Gooen, 2017; Lee, Hartridge, Corbett, Vittinghoff, & Auerbach, 2015)
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APPENDIX J 
PDSA Cycles 
 
Interval 1 
 
 
Interval 2 
 
 
 
Interval 3 
 
 
Interval 4 
 
